Search

Displaying results 3431 - 3440 of 10000 in total
  1. Drug

    Bronopol

    go.drugbank.com/drugs/DB13960
    Approved

    First synthesized in 1897, bronopol was primarily used as a preservative for pharmaceuticals and was registered in the United States in 1984 for use in industrial bactericides, slimicides and preservatives … The agent is largely available commercially as an antibacterial for a variety of industrial purposes while it is predominantly available for purchase as a pet animal litter antibacterial at the domestic

  2. Drug

    SI-109

    go.drugbank.com/drugs/DB32603
    Experimental

    SI-109 is a potent, small-molecule inhibitor of the STAT3 SH2 domain.[A275443]

  3. Drug

    AZD-2836

    go.drugbank.com/drugs/DB06031
    Investigational

    AZD-2836 is an inhibitor of the nonstructural protein 5A (NS5A).[A264853] The drug is being investigated for treatment of hepatitis C because AZD-2836 has in vitro anti-HCV activity.[A264858]

  4. Drug

    Poliovirus type 3 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10797
    ApprovedInvestigational

    Poliovirus type 3 antigen is a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis

    Mixtures: HEXAXIM 0.5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇEREN FLAKON, 1 ADET, TETRAXIM 0.5 ML IM ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET
  5. Drug

    CPO-107

    go.drugbank.com/drugs/DB18492
    Investigational

    CPO-107 is a CD20-CD47 bispecific fusion protein

  6. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    [L53198,L53208] FAK is important for the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key … [L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersSynonyms: N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide
  7. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    Originally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pivoted toward oncology as a potent sensitizing … [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089]

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2C8 Inducers
  8. Drug

    Andexanet alfa

    go.drugbank.com/drugs/DB14562
    Approved

    It was developed by Portola Pharmaceuticals and was approved in in May 2018. … Rivaroxaban and apixaban are Factor Xa inhibitors that promote anticoagulation in situations where blood clotting is unfavourable, such as in deep vein thrombosis and pulmonary embolism.

  9. Drug

    Magnesium silicate

    go.drugbank.com/drugs/DB13249
    ApprovedWithdrawn

    [L2603] Under the FDA, magnesium silicate is determined as a member of the substances generally recognized as safe (GRAS) to be used as an anticaking agent.[L2605] … The molecular formula can be expressed more clearly as MgSiO3.xH2O.[T186] It is known as talc and it presents many uses in the cosmetic industry, food industry and pharmaceutical industry.

  10. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    [A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. … Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor

    Synonyms: 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl) benzoic acid, BENZOIC ACID, 4-((2S,4S)-4-ETHOXY-1-((5-METHOXY-7-METHYL-1H-INDOL-4-YL)METHYL)-2-PIPERIDINYL)-Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates